XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Note 7 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities (in shares) 10,000 10,000
Convertible Series F Preferred Stock [Member]    
Antidilutive Securities (in shares) [1] 1,964,986 3,728,070
Series F Preferred Warrants [Member]    
Antidilutive Securities (in shares) [2] 111,396,848 19,152,047
Common Stock Warrants [Member]    
Antidilutive Securities (in shares) [3] 5,101,345 4,139,784
[1] Calculation assumes conversion of the stated value, and accrued dividends, of the Series F Preferred Stock into Common Stock at the Floor Price as of June 30, 2024, and at the initial conversion price of $1.71 as of June 30, 2023.
[2] Calculation assumes exercise of the Series F Preferred Warrants for cash into Series F Preferred Stock and subsequent conversion of the Series F Preferred Stock into Common Stock at the Floor Price as of June 30, 2024 and at the initial conversion price of $1.71 as of June 30, 2023.
[3] Calculation does not include the 963,745 Common Warrants issued during the three and six months ended June 30, 2024, as they were not exercisable as of June 30, 2024.